Digest Network Come funziona
Network
/
Società
Gi
Non verificato

Gilead Sciences, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteSanità

137 comunicati stampa

Guarda tutti i comunicati
24/07/2026
Industria
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
21/07/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Sanità
Farmaceutica
Salute
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
21/07/2026
Eventi
Fiere
Industria
Biotecnologia
Farmaceutica
HIV, AIDS e malattie autoimmuni
Sanità
Salute
Medicina - Varie
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
21/07/2026
Mercato del lavoro
Industria
HIV, AIDS e malattie autoimmuni
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
24/06/2026
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
23/06/2026
Industria
Biotecnologia
Igiene alimentare
Salute
Sanità
Farmaceutica
Oncologia
Scienza
Medicina - Varie
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
15/06/2026
Industria
HIV, AIDS e malattie autoimmuni
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
12/06/2026
Industria
Salute
HIV, AIDS e malattie autoimmuni
Sanità
Farmaceutica
Biotecnologia
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
11/06/2026
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
08/06/2026
Multimedialità
Industria
Scienza
Sanità
Farmaceutica
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Igiene alimentare
Salute
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0